HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E1734 OD36 OD36 is an inhibitor of RIPK2 with an IC50 value of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. Dec 24 2023
E2983 PF-04957325 PF-04957325 is a highly potent and selective inhibitor of PDE8, with IC50 values of 0.7 nM and 0.3 nM for PDE8A and PDE8B, respectively. PF-04957325 greatly potentiates steroidogenesis in wild type adrenal cells. Dec 20 2023
E1618 TC-S 7009 TC-S 7009 is a potent and selective inhibitor of HIF-2α with a Kd value of 81 nM. TC-S 7009 is more selective for HIF-2α than HIF-1α. It disrupts HIF-2α heterodimerization, decreases DNA-binding activity, and reduces HIF-2α target gene expression. Dec 20 2023
S2520 CD437(AHPN) CD437(AHPN), a synthetic retinoid, is a selective Retinoic acid Receptor γ ( RARγ) agonist. It exhibits an antiproliferative effect and induces apoptosis via activation of AP-1 in vitro. Dec 18 2023
E1780 Alexidine dihydrochloride Alexidine dihydrochloride, a dibiguanide compound, is an effective and selective inhibitor of protein tyrosine phosphatases localized to mitochondrion 1 (PTPMT1) with an IC50 of 1.08 μM in vitro. It has the potential to treat type II diabetes. Dec 18 2023
E1605 Avotaciclib trihydrochloride Avotaciclib trihydrochloride(BEY1107 trihydrochloride) is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). It can be used for the research of locally advanced or metastatic pancreatic cancer. Dec 17 2023
E1678 SPOP-i-6lc SPOP-i-6lc is a selective speckle-type POZ protein (SPOP) E3 ubiquitin ligase inhibitor with IC50 of 2.1 μM and 3.5 μM, in A498 and OS-RC-2 cell lines, respectively. In vitro, It suppresses viability and proliferation of A498 and OS-RC-2 kidney cancer cell lines. Dec 17 2023
E1743 VX-561(CTP-656) VX-561 (CTP-656) is a potent CFTR modulator and exhibits an EC50 value of 255 nM for CFTR potentiation in G551D/F508del HBE cells. Dec 17 2023
A3174 Mosunetuzumab (Anti-CD20 & CD3e) Mosunetuzumab (Anti-CD20 & CD3e) is expressed from CHO. The heavy chain type is IgG1, and the light chain type is hukappa. MW: 146.72 kDa. Dec 14 2023
E1028 POMHEX POMHEX, is a potent ENO2 -specific inhibitor of enolase and a racemic mixture, a cell-permeable pivaloyloxymethyl (POM) prodrug of HEX. It is also glycolysis inhibitor and can be used for the research of cancer. Dec 13 2023
E1203 Sirpiglenastat Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. It has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response with immunomodulatory and antineoplastic activities. Dec 13 2023
S8091 25-Hydroxycholesterol 25-Hydroxycholesterol is a side-chain oxysterol and a selective suppressor of IgA production by B cells with an EC50≈65 nM. It affects the immune system and has a key role in the pathogenesis of atherosclerosis. Dec 12 2023
E1409 Zidesamtinib Zidesamtinib (NVL-520) is a potent brain-penetrating inhibitor of ROS1 tyrosine kinase with IC50 of 0.7 nM for wild-type ROS1 . It acts as a potential antineoplastic agent and can be used for the research of cancer. Dec 11 2023
S8395 INDY INDY, a benzothiazole derivative is a potent and ATP-competitive inhibitor of Dyrk1A and Dyrk1B with an IC50 value of 0.24 μM and Ki value of 0.18 μM, respectively. INDY diminishes the self-renewal capacity of normal and tumorigenic cells in primary Glioblastoma (GBM) cell lines and neural progenitor cells. Dec 11 2023
E1636 MV1035 MV1035, an inhibitor of ALKBH5 significantly reduces GBM U87-MG cell migration and invasiveness through inhibition of the RNA demethylase ALKBH5. Dec 11 2023
E1598 VT103 VT103 is an orally active and selective inhibitor of TEAD1 protein palmitoylation with anti-proliferative and anti-tumor activity. It also inhibits YAP/TAZ-TEAD promoted gene transcription, blocks TEAD auto-palmitoylation and disrupts interaction between YAP/TAZ and TEAD. Dec 07 2023
E1735 PK11007 PK11007 is a thiol-reactive anticancer agent that stabilizes p53 via selective alkylation of two surface cysteines without compromising its DNA binding. It induces mutant p53 cancer cell death by increasing reactive oxygen species (ROS) levels. Dec 07 2023
E1684 C1632 C1632 (Lin28-let-7 antagonist 1) is a RNA-binding protein and a potent antagonist of Lin28/pre-let-7 interaction. It inhibits Lin28A binding to pre-let-7a-2, with an IC50 of 8 μM as well as inhibits proliferation in human cancer cells. Dec 07 2023
E1512 M3541 M3541 is a potent and selective inhibitor of ATM kinase activity with an IC50 value of 0.25 nM in cell-free assays. M3541 suppresses double-strand breaks (DSB) repair, clonogenic cancer cell growth and potentiates antitumor activity of ionizing radiation in cancer cell lines. Dec 06 2023
E1638 ALKBH5 inhibitor 2 (Cpd 20m) ALKBH5 inhibitor (Cpd 20m) is a potent and selective inhibitor of RNA m6A demethylase AlkB homolog 5 ALKBH5 with IC50 of 21 nM. Dec 05 2023